Detailed price information for Prelude Therapeutics Inc (PRLD-Q) from The Globe and Mail including charting and trades.

Updated clinical data from VISTA101 presented at SITC 2024. Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by year-end. Encouraging clinical responses observed in ...

She previously served as Chief Executive Officer at Harpoon Therapeutics until the company’s acquisition by Merck in early 2024. In addition to Ms. Eastland’s appointment, Ingmar Bruns, M.D., has been ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

Innovative drug development "the flavor of 2025" says Ali Pashazadeh, who discusses how the new administration will likely ...

He was a pioneer of new methods in the industry, being one of the first to focus on R&D as well as manufacturing ... whilst “American” Merck (now Merck & Co. in the US or Merck Sharp ...

On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced ...

It’s a good place to develop, with generous government incentives, including a Research & Development (R&D) rebate. There are ...

Vaccine maker shares closed lower Thursday amid reports that Donald Trump was set to nominate vaccine critic Robert F.

Which is the best company to work for in the Asia-Pacific region? Many, if not most, executives might claim that theirs is — ...